Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sensyne Health signs exclusive licence agreement for a digital health software product, Support-HF

The Oxford-based firm said Support-HF will help patients and clinicians in managing heart failure and curate data for medical research using Clinical AI
AI
Sensyne said it also plans to develop a cloud-based scalable version of Support-HF

Sensyne Health Ltd, which is set to list on AIM on August 17, said on Wednesday that it has signed an exclusive licence agreement for a digital health software product, Support-HF, with the University of Oxford and Oxford University Hospitals NHS Foundation Trust.

The Oxford-based firm, which uses artificial intelligence (AI) to develop medicines said Support-HF will help patients and clinicians in managing heart failure and curate data for medical research using Clinical AI.

READ: Sensyne Health planning to raise £60mln via AIM IPO, according to founder Paul Drayson

The company said it also plans to develop a cloud-based scalable version of Support-HF to help support the management of heart failure at home.

The collaboration, which was established in July last year, creates a pathway for the commercial development of digital health innovations invented and clinically validated by the University and the Trust, Sensyne said.

In a statement on the group’s website, Sensyne founder and chief executive Paul Drayson commented: "Support HF has the potential to make significant improvements in the care of patients suffering from heart failure and is a further example of the pipeline of digital health innovations coming out of research at Oxford.”

Drayson, a peer and a former Labour government minister in the 2000’s added: "Sensyne Health will now develop the product so that it may be deployed more widely across the NHS and then internationally.”

View full SENS profile View Profile

Sensyne Heath PLC Timeline

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use